What Researchers Did
This review article summarized the latest information on how to manage necrotizing soft-tissue infections, including recent data on epidemiology, microbiology, and clinical treatment approaches.
What They Found
The review found that necrotizing soft-tissue infections (NSTI) can be caused by many organisms, with increasing reports of multidrug-resistant bacteria. Morbidity and mortality for NSTI remain high, ranging from 20% to over 30%. The value of additional treatments like intravenous immunoglobulin and hyperbaric oxygen therapy is currently uncertain.
What This Means for Canadian Patients
For Canadian patients with necrotizing soft-tissue infections, this review emphasizes that prompt diagnosis, early radical surgery, and broad-spectrum antibiotics are the most important treatments. While hyperbaric oxygen therapy may be considered, its overall benefit for this condition is still not clearly established by current evidence. Patients should discuss all treatment options with their healthcare team.
Canadian Relevance
No direct Canadian connection identified.
Study Limitations
A key limitation of this review is the ongoing uncertainty regarding the effectiveness of adjunctive therapies like hyperbaric oxygen, indicating a lack of strong clinical evidence in this area.